CATO SMS is here to support you!
Learn more below how we can help you move forward.
We know there are issues arising from the COVID-19 pandemic that may affect your clinical trial and cause delays. CATO SMS is here to support you! We can assist in the design, refinement, or modification of development plans, accelerate clinical trial preparations, and develop insightful regulatory approval strategies. We can further use cutting-edge, proven technologies to mitigate disruptions at investigator sites and maintain clinical trial momentum.
In order to keep pace, CATO SMS – a CRO with proven performance in complex research areas - (immuno-) oncology, orphan diseases, cell/gene therapy, and advanced therapeutics – can support you in all aspects of therapeutics development during these unprecedented times:
Contact our Business Development teams in North America or Europe now to see how we can collaborate from strategy to approval.
At CATO SMS, our number one priority is the safety and well-being of trial participants, employees, and sponsors, and we recognize our responsibility to the communities in which we live and work. We send our best wishes to you and your loved ones during this difficult time.
CATO SMS is a full-service clinical and regulatory contract research organization (CRO), specializing in complex areas such as (immuno-) oncology, advanced therapeutics and orphan diseases. We offer regulatory consulting and drug development affairs in addition to clinical trial management services, leveraging the experience and expertise in all disciplines to the full benefit of your company. We are committed to supporting small and mid-sized biotech, top-tier pharmaceutical companies and investigator groups from strategy to approval, from phase I to IV. CATO SMS employs over 320 dedicated professionals with offices and operations in over 25 countries around the globe including the United States (US), Canada, Europe, Israel and South Africa. Offices are strategically located close to the European Medicines Agency (EMA) in Amsterdam, the Netherlands, and the Food and Drug Administration (FDA) in Washington, US